This study is a continuation of the placebo-controlled study CE1226_4001 (NCT00261833) to evaluate the efficacy and safety of Zemaira® i.v. administration in subjects with emphysema due to alpha1-proteinase inhibitor deficiency.
CSL Behring announced that The Lancet Respiratory Medicine published findings of the RAPID Open Label Extension study of Zemaira (alpha1...
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Respreeza (alpha1-antitrypsin),...